GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary

Management is intentionally shifting the business model toward Pharma Manufacturer Solutions (rebranded as Pharma Direct) to capture the growing trend of direct-to-consumer pharmaceutical commercialization. The core Rx Marketplace faced headwinds from the Rite Aid bankruptcy and lower volumes in specific Integrated Savings Program partnerships, totaling an approximately $35 million-$40 million impact in 2025. Strategic focus has moved toward high-intent, condition-specific subscriptions in areas like ...